Biotech Values

[DewDiligence]

Survey on Mystery Bidder for IMCL

Background: A PR from IMCL yesterday stated that an unnamed pharmaceutical company has tentatively offered $70/sh to acquire IMCL, subject to conducting further DD under a confidentiality agreement. BMY previously offered to acquire IMCL unconditionally at $60/sh.

Q: Which of the following most closely matches your
view regarding the identity of the new IMCL suitor?

a) PFE
b) GSK
c) SNY
d) NVS
e) Roche/DNA
f) AMGN
g) Merck Serono
h) A US- or European-based pharma/biotech other than PFE GSK SNY NVS Roche/DNA AMGN or Merck-Serono
i) A Japanese pharma
j) drbio
k) There is no bona fide suitor—the PR from IMCL is a sham

To vote, go to
http://www.investorshub.com/boards/board_surveymenu.asp?board_id=1418
and select survey #105.